|Public limited company|
|Traded as||LSE: GSK
Beecham Group plc
Kline & French
|Chris Gent (Chairman)
Andrew Witty (CEO)
|Products||Pharmaceuticals, vaccines, oral healthcare products, nutritional products, over-the-counter medicines|
|Revenue||£23.006 billion (2014)|
|£3.597 billion (2014)|
|£2.831 billion (2014)|
Number of employees
|Over 100,000 (2015)|
|Slogan||"Do more, feel better, live longer"|
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of 2014 it was the world's sixth-largest pharmaceutical company after Johnson & Johnson, Novartis, Hoffmann-La Roche, Pfizer and Sanofi, measured by 2013 revenue. The company was established in 2000 by the merger of Glaxo Wellcome (formed from the acquisition of Wellcome plc by Glaxo plc) and SmithKline Beecham plc (from the merger of Beecham Group plc and SmithKline Beckman Corporation, which in turn was formed by combining the Smith, Kline & French and Beckman companies).
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of 2 May 2014 it had a market capitalisation of £79 billion, the fourth-largest of any company listed on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange. Andrew Witty has been the chief executive officer since May 2008.
GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental-health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal in 2013. Many medicines were discovered or developed at GSK and its predecessor companies and are now sold as generics. Its drugs and vaccines earned £21.3 billion in 2013. GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare and nutritional products, drinks and over-the-counter medicines, including Sensodyne, Boost and Horlicks.
In 2012 GSK pleaded guilty to criminal charges in the United States, and agreed to pay a $3 billion (£1.9bn) settlement, including a criminal fine of $1 billion. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company. The charges related to GSK's promotion of several drugs for unapproved uses, including the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion), kickbacks to physicians, a failure to report safety data about the diabetes drug Avandia (rosiglitazone), and reporting false prices to Medicaid. The company announced in 2013 that it would no longer pay physicians to promote its drugs.
In 2014 the company applied for regulatory approval for the first vaccine against malaria. The company has committed to make the vaccine available in developing countries for a price set at 5% above the cost of production.
- 1 History
- 2 Company profile
- 3 Controversies
- 4 See also
- 5 References
- 6 External links
Glaxo was founded by a Londoner, Joseph Nathan, in the 1850s in Bunnythorpe, New Zealand, as a general trading company. In 1904 it began producing dried-milk baby food, first known as Defiance, then as Glaxo, under the slogan "Glaxo builds bonny babies". The sign is still visible on what is now a car repair shop on the main street of Bunnythorpe.
Burroughs Wellcome & Company was founded in 1880 in London by the American pharmacists Henry Wellcome and Silas Burroughs. The Wellcome Tropical Research Laboratories opened in 1902. In 1959 the Wellcome Company bought Cooper, McDougall & Robertson Inc. to become more active in animal health.
Glaxo became Glaxo Laboratories and opened new units in London in 1935. Glaxo Laboratories bought two companies, Joseph Nathan and Allen & Hanburys in 1947 and 1958 respectively. After the company bought Meyer Laboratories in 1978, it began to play an important role in the US market. In 1983 the American arm, Glaxo Inc., moved to Research Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North Carolina. Burroughs Wellcome and Glaxo merged in 1995 to form Glaxo Wellcome. Glaxo restructured is R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening a Medicines Research Centre in Stevenage, Hertfordshire. Also in that year, Glaxo Wellcome acquired the California-based Affymax, a leader in the field of combinatorial chemistry.
In 1999 Glaxo Wellcome was the world's third-largest pharmaceutical company by revenues (behind Novartis and Merck), with a global market share of around 4 per cent. Its products included Imigran (for the treatment of migraine), salbutamol (Ventolin) (for the treatment of asthma), Zovirax (for the treatment of coldsores), and Retrovir and Epivir (for the treatment of AIDS). As of 2000 seven of its products were among the world's top 50 best-selling pharmaceutical products, and it was the world's largest maker of drugs for the treatment of asthma and HIV/AIDS. It employed 59,000 people worldwide, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide. In the UK the company had R&D facilities at Ware and Stevenage, Hertfordshire, Dartford and Beckenham, Kent, Greenford in London, and manufacturing plants at Ulverston in Cumbria, Barnard Castle in County Durham, Speke on Merseyside, and Montrose in north-east Scotland. Outside the UK, it had R&D centres in North Carolina, United States and Japan, and production facilities in the United States, Europe and the Far East.
In 1843 Thomas Beecham launched his Beecham's Pills laxative in England giving birth to the Beecham Group. Beecham opened its first factory in St Helens, Lancashire, England, for rapid production of medicines in 1859. The original factory was closed in 1994 and passed to the local college for re-development. By the 1960s Beecham was extensively involved in pharmaceuticals.
In 1830 John K. Smith opened its first pharmacy in Philadelphia. In 1865 Mahlon Kline joined the business, which 10 years later became Smith, Kline & Co. In 1891 it merged with French, Richard and Company. It changed its name to Smith Kline & French Laboratories in 1929 as it focused more on research. Years later Smith Kline & French Laboratories opened a new laboratory in Philadelphia; it then bought Norden Laboratories, a business doing research into animal health. Smith Kline & French Laboratories bought Recherche et Industrie Thérapeutiques (Belgium) in 1963 to focus on vaccines. The company started to expand globally, buying seven laboratories in Canada and the US in 1969. In 1982 it bought Allergan, a manufacturer of eye and skincare products. The company merged with Beckman Inc. later that year and changed its name to SmithKline Beckman.
In 1988 SmithKline Beckman bought its biggest competitor, International Clinical Laboratories, and in 1989 merged with Beecham to form SmithKline Beecham plc. The headquarters of the company was moved to England. To expand research and development in the US, SmithKline Beecham bought a new research center in 1995. Another new research centre at New Frontiers Science Park in Harlow, England, was opened in 1997. Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000; the merger was completed in December that year, forming GlaxoSmithKline (GSK).
GSK House, world headquarters of GlaxoSmithKline in Brentford, London
GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal in 2013. Its drugs and vaccines earned £21.3 billion in 2013. Top-selling products include its asthma/COPD therapeutics Advair, Ventolin, and Flovent; its diphtheria/tetanus/pertussis vaccine Infanrix and its hepatitis B vaccine; the epilepsy drug Lamicatal; the antihyperlipemia drug Lovaza; and the antibacterial Augmentin.:220 Its consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, and nutritional products, drinks and over-the-counter medicines, including Sensodyne, Boost and Horlicks.
Medicines historically discovered or developed at GSK and its legacy companies and now sold as generics include amoxicillin and amoxicillin-clavulanate, ticarcillin-clavulanate, mupirocin, and ceftazidime for bacterial infections, zidovudine for HIV infection, valacyclovir for herpes virus infections, albendazole for parasitic infections, sumatriptan for migraine, lamotrigine for epilepsy, bupropion and paroxetine for major depressive disorder, and cimetidine and ranitidine for gastroesophageal reflux disorder. Among these, amoxicillin, amoxicillin-clavulanate, mupriocin, zidovudine, albendazole, and ranitidine are listed on the World Health Organization's list of essential medications.
The company's over-the-counter health-care products include Abreva to treat cold sores; Aquafresh, Maclean's and Sensodyne toothpastes; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements. It also sells several drinks, including Horlicks, a malted milk drink and Boost, a chocolate-flavoured drink, and formerly sold Lucozade, marketed as an energy drink, and Ribena, a fruit drink.
As of 2013 GSK has offices in over 115 countries. Its global headquarters are in the UK at GSK House in Brentford, a suburb of west London, and its US headquarters are in The Navy Yard, Philadelphia and Research Triangle Park, North Carolina. The company employs over 99,000 people, 12,500 of whom work in research and development.:7 The company's single largest market is the United States. Its consumer-products division is based in the Pittsburgh suburb of Moon Township, Allegheny County, Pennsylvania. The research-and-development division has major facilities in south-east England, Philadelphia and North Carolina. Company facilities include:
- R&D sites in Stockley Park, Stevenage and Ware, England; Zagreb, Croatia; Évreux and Les Ulis, France; Research Triangle Park, North Carolina, and Collegeville, Pennsylvania, US; Laval, Quebec, Canada; Shanghai, China; and Nashik, Maharashtra, India.
- Centres for biopharmaceutical products in Wavre and Rixensart, Belgium; Dresden, Germany; Gödöllő, Hungary; Quebec City, Canada; Marietta, Pennsylvania and Hamilton, Montana, US.
- Manufacturing sites for prescription products in Irvine and Montrose, Scotland; Ware, Barnard Castle, Worthing and Ulverston, England; Cork, Ireland; Évreux, France; Poznań, Poland; Parma, Italy; Brașov, Romania; Brussels, Belgium; Bristol, Tennessee, King of Prussia, Pennsylvania and Zebulon, North Carolina, US; Cidra, Puerto Rico; Jurong, Singapore; Ulu Klang, Malaysia; Boronia, Australia.
- Manufacturing sites for consumer products in Maidenhead, England; Dungarvan, Ireland; Mississauga, Ontario, Canada; Aiken, South Carolina, Oak Hill, New York and St. Louis, Missouri, US; and Kenya; Rio de Janeiro, Brazil.
Operations and acquisitions
In 2001 GSK completed the acquisition of New Jersey-based Block Drug for US$1.24 billion. In July 2002 GSK House, located in Brentford, London, was officially opened as GSK's new world headquarters by then-Prime Minister Tony Blair. The building was erected at a cost of £300 million and is home to around 3,000 staff. In October 2006 GSK acquired the US-based consumer healthcare company CNS Inc., whose products included Breathe Right nasal strips and FiberChoice dietary fibre supplements, for US$566 million in cash. GSK opened its first R&D centre in China in May 2007, located in Shanghai, and initially focused on neurodegenerative diseases.
In April 2009 GSK acquired Stiefel Laboratories, the world's largest independent dermatology drug company at the time, for US$2.9 billion, assuming $400 million in debt and with a potential of $300 million in performance-based milestone payments, for a total of US$3.6 billion (£2.5 billion).
On 16 November that year the US Food and Drug Administration (FDA) announced that a vaccine for 2009 H1N1 influenza protection (manufactured by GSK's ID Biomedical Corp. subsidiary) would join the four vaccines approved on 15 September. Also in November 2009 GSK formed a joint venture with Pfizer to create ViiV Healthcare. Viiv Healthcare received all of Pfizer and GSK's HIV assets. ViiV Healthcare is 85 percent owned by GSK and 15 percent by Pfizer.
In June 2010 the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company, for $253m, and in December the UK-based sports nutrition company Maxinutrition for £162 million (US$256 million). In December 2011, in a $660-million deal, Prestige Brands Holdings took over 17 GSK brands with sales of $210 million, including BC Powder, Beano, Ecotrin, Fiber Choice, Goody's Powder, Sominex and Tagamet.
In March 2012 the company announced that it would invest £500 million in manufacturing facilities in Ulverston, northern England, designating it as the site for a previously announced biotech plant. In May it acquired CellZome, a German biotech company, for US$98 million. In June, through its Stiefel subsidiary, GSK acquired worldwide rights to alitretinoin (Toctino), an eczema drug, for $302 million.
In 2013 the company said it would seek marketing approval for the world's first malaria vaccine in 2014. In July that year it acquired United States-based biopharmaceutical company Human Genome Sciences for $14.25 a share, or $3 billion. HGS and GSK had already collaborated on the development of two drugs that received marketing approval, the lupus drug Belimumab (Benlysta) and albiglutide for type 2 diabetes, and on a drug in development darapladib for atherosclerosis.
In March 2014 GSK paid $1 billion to raise its stake in its Indian pharmaceutical unit, GlaxoSmithKline Pharmaceuticals, to 75 percent as part of a move to focus on emerging markets. Also that month it recalled Alli, an over-the-counter weight-loss drug, in the US and Puerto Rico because of possible tampering, following customer complaints in seven states. In April Novartis and Glaxo agreed on more than $20 billion in deals, with Novartis selling its vaccine business to GSK and buying GSK's cancer business. In February 2015 GSK announced that it would acquire GlycoVaxyn, a Swiss pharmaceutical company, for $190 million.
Since 2010 GlaxoSmithKline has several times ranked first among pharmaceutical companies on the Global Access to Medicines Index, which is funded by the Bill and Melinda Gates Foundation. In 2014 the Human Rights Campaign, an LGBT-rights advocacy group gave GSK a score of 100% in its Corporate Equality Index.
GSK has been active, with the World Health Organization (WHO), in the Global Alliance to Eliminate Lymphatic Filariasis (GAELF). Around 120 million people globally are believed to be infected with lymphatic filariasis. In 2012 the company endorsed the London Declaration on Neglected Tropical Diseases, a collaborative disease eradication programme. Under this agreement GSK committed to donating 400 million albendazole tablets to the WHO each year to fight soil-transmitted helminthiasis, and to continue to provide 600 million albendazole tablets every year for lymphatic filariasis until the disease is eradicated.
Since 2004 the company has collaborated with the Bill & Melinda Gates Foundation and the PATH Malaria Vaccine Initiative in the development of a vaccine for malaria, responsible for over 650,000 deaths per year, mainly in Africa. As of 2013 RTS,S, which uses GSK's proprietary AS01 adjuvant, was being examined in a Phase 3 trial in eight African countries. PATH reported that "[i]n the 12-month period following vaccination, RTS,S conferred approximately 50% protection from clinical Plasmodium falciparum disease in children aged 5-17 months, and approximately 30% protection in children aged 6-12 weeks when administered in conjunction with Expanded Program for Immunization (EPI) vaccines." In 2014 Glaxo said it had spent more than $350 million, and expected to spend an additional $260 million before seeking regulatory approval.
In 2009 the company said it would cut drug prices by 25 percent in 50 of the poorest nations, release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development, and invest 20 percent of profits from the least-developed countries in medical infrastructure for those countries. Médecins Sans Frontières welcomed the decision, but criticized GSK for failing to include HIV patents in its patent pool, and for not including middle-income countries in the initiative.
Lobbying and political activities
In 2013, GlaxoSmithKline spent between €600,000 and €650,000 lobbying European Union institutions and $3,720,000 on federal lobbying activities in the United States. Additional indirect expenditures were made through membership in national and international trade organizations. The company does not directly contribute to the political candidates, but in 2013 U.S. members of the GSK employee political action committee contributed $484,810 to political campaigns in the United States. Approximately 60% of this amount was donated to Republican candidates and 40% to Democrats.
2012 criminal and civil settlement
In July 2012 GSK pleaded guilty to criminal charges and agreed to a pay $3 billion in the largest settlement by a drug company at the time. The criminal charges were for promoting its antidepressants, Paxil and Wellbutrin, for unapproved uses from 1998-2003, and failing to report safety data about Avandia, both in violation of the Federal Food, Drug, and Cosmetic Act; GSK paid $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600. The remaining $2 billion were part of the civil settlement over (1) promoting the drugs Paxil, Wellbutrin, Advair, Lamictal and Zofran for off-label, non-covered uses and paying kickbacks to physicians to prescribe those drugs as well as the drugs Imitrex, Lotronex, Flovent and Valtrex; (2) making false and misleading statements concerning the safety of Avandia; and (3) reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program. GSK also signed a five-year Corporate Integrity Agreement with the U.S. Department of Health and Human Services, which obligated GSK to make major changes to the way it did business, including changing the way its sales force is compensated and its executive compensation program, and to implement and maintain transparency in its research practices and publication policies. The government investigation was launched largely on the basis of information provided by four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the U.S. False Claims Act.
In June 2007 a meta-analysis by Steve Nissen of the Division of Cardiovascular Medicine at the Cleveland Clinic, published in the New England Journal of Medicine, showed an increased odds ratio of myocardial infarction in patients taking rosiglitazone, marketed as Avandia. The New York Times published an article detailing Nissen's conversation with pharmaceutical executives; the conversations had been recorded, unbeknownst to the GSK executives. A Congressional investigation was subsequently initiated to determine what information was known at the time of the drug's approval, as well as post approval, and whether GSK had wilfully suppressed such information. In February 2010 GSK tried to suppress publication of a critical article. In November 2007 a United States congressional committee released a report describing intimidation of Dr. John Buse (University of North Carolina at Chapel Hill) by GSK over his concerns about the cardiovascular risks associated with rosiglitazone.
In 2013 the FDA held a joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the results of RECORD, an open label, randomized trial comparing rosiglitazone to the combination of a sulfonylurea with metformin. In contrast to the mostly short-term trials included in the Nissen meta analysis, RECORD was designed to examine cardiovascular safety in a trial of 14,000 people observed over three years or more. An independent analysis of the data from this trial conducted at the Duke Clinical Research Institute found a non-statistically significant reduction in all-cause mortality, for rosiglitazone compared to the combination of metformin with a sulfonylurea (hazard ratio 0.86), and a non-statistically significant increase in the risk of myocardial infarction (hazard ratio 1.15). The reliability of the conclusions of the RECORD trial has been criticized based on its open-label design and the low rate of cardiovascular events observed, which limits its statistical power. In November 2013 the FDA lifted restrictions on the sale of Avandia, stating that the results of the RECORD trial had failed to confirm Nissen's analysis.
Paroxetine (Paxil, Seroxat)
Paroxetine is an SSRI anti-depressant released by GSK in 1992, sold as Paxil, Seroxat, Aropax, Brisdelle, Pexeva and Sereupin. GSK paid substantial fines, as well as settlements in class-action lawsuits, in relation to its marketing of the drug, in particular the off-label marketing of paroxetine to children, the suppression of negative research results relating to its use in children, and allegations that it failed to warn consumers of substantial withdrawal effects. For 10 years the drug was marketed as "not habit forming". In 2003 the World Health Organization reported that it was among the top 30 drugs, and top three antidepressants, for which dependence had been reported (91 cases). In 2004 GSK agreed to settle charges of consumer fraud for $2.5 million; the drug had annual sales worth $2.7 billion at the time. The suppression of the unfavorable research findings was the subject of Side Effects (2008) by Alison Bass.
SB Pharmco Puerto Rico
In October 2010 the US Department of Justice announced that SB Pharmco Puerto Rico Inc., a subsidiary of GSK, agreed to pay $750 million in fines related to problems at GSK's premier manufacturing plant in Puerto Rico between 2001 and 2005. The factory had been closed by GSK in 2009. GSK agreed to pay the settlement in response to complaints stemming from production of adulterated drugs at its manufacturing plant in Puerto Rico, which at the time produced $5.5 billion of products each year. According to the New York Times, the case began in 2002 when GSK sent a team of quality experts to fix problems cited by an FDA warning letter a month earlier. The lead inspector complained to senior managers and recommended recalls of defective products, but they were not authorised, and she was fired in 2003. She eventually notified the FDA and filed a whistleblower lawsuit. In 2005 federal marshals seized $2 billion worth of products, the largest such seizure in history. In the 2010 settlement, SB Pharmco pled guilty to criminal charges, and agreed to pay $150 million in a criminal fine and forfeiture, at that time the largest such payment ever by a manufacturer of adulterated drugs, and $600 million in civil penalties to settle the civil lawsuit.
Ribena is a blackcurrant-based soft drink originally marketed by HW Carter in the 1930s. The brand had a reputation as a healthy product in the UK and Commonwealth, stemming from its use as a source of Vitamin C for children during World War II. Beecham bought HW Carter in 1955.
A series of scandals in the 2000s damaged the brand's reputation. In 2001 the Advertising Standards Authority in the UK ruled that GSK's claim that Ribena Toothkind, which contains sugar, "benefited oral health" was misleading. The drink's sugar content is lower than regular Ribena; company ads included a poster showing bottles of Toothkind in place of the bristles on a toothbrush. The ruling was upheld by the High Court. In 2007 GSK pleaded guilty to 15 charges brought by New Zealand's Commerce Commission related to the company's claim that ready-to-drink Ribena contained high levels of vitamin C. The Commission's testing found that it contained no detectable vitamin C. The company was fined $217,000.
- A bribery investigation was opened in Bavaria, Germany in 1999, with thousands of doctors and nearly all of SmithKline Beecham's sales force under investigation; by 2004, only 71 doctors and dozens of employees remained under investigation. As of 2014, further information on the outcome of the German investigations was not available.
- On 12 September 2006 GSK settled the largest tax dispute in IRS history, agreeing to pay $3.1 billion. At issue in the case were Zantac and the other Glaxo Group heritage products sold in 1989–2005. The case was about an area of taxation dealing with intracompany "transfer pricing"—determining the share of profit attributable to the US subsidiaries of GSK and subject to tax by the IRS. Taxes for large multi-divisional companies are paid to revenue authorities based on the profits reported in particular tax jurisdictions, so how profits were allocated among various legacy Glaxo divisions based on the functions they performed was central to the dispute in this case.
- In July 2013 Chinese authorities announced that since 2007 more than 700 travel agencies and consulting firms had been used by GSK to funnel nearly three billion yuan (HK$3.8 billion) in kickbacks to GSK managers, doctors, hospitals and others who prescribed their drugs. GSK issued a statement expressing concern and disappointment, and said it would co-operate with the investigation. In July the company admitted that some of its senior Chinese executives broke the law; Chinese authorities arrested four executives as part of a four-month investigation into claims that doctors were bribed with cash and sexual favours in return for prescribing GSK's drugs. By July 2014 the four executives had yet to be put on trial, when a former GSK investigator described the bribery claims as credible. In September 2014, a Chinese court found the company guilty of bribery, fined the company $490 million, and gave Mark Reilly, the former head of Chinese operations, a three-year suspended prison sentence.
- In May 2014, the UK's Serious Fraud Office launched a formal criminal investigation using powers granted by the Bribery Act 2010 into commercial practices at GSK, but it was not revealed what connection there was to other investigations.
- "Preliminary Results 2014" (PDF). Retrieved 15 March 2015.
- "About us". GlaxoSmithKline. Retrieved 15 May 2014.
- Eric Palmer, "The top 10 pharma companies by 2013 revenue", FiercePharma, 4 March 2014.
- "FTSE All-Share Index Ranking". stockchallenge.co.uk. Retrieved 15 May 2014.
- "Corporate Executive Team"[dead link], GlaxoSmithKline. Retrieved 16 November 2013.
- "Products". GlaxoSmithKline plc. Retrieved 16 November 2013.
- Katie Thomas and Michael S. Schmidt (2 July 2012). "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times.
Simon Neville, "GlaxoSmithKline fined $3bn after bribing doctors to increase drugs sales", The Guardian, 3 July 2012.
Nigel Hawkes (7 November 2011). "GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugs". British Medical Journal.
- "GSK to stop paying doctors in major marketing overhaul". Thomson/Reuters. Retrieved 27 October 2014.
- "Glaxo Files Its Entry in Race for a Malaria Vaccine - WSJ".
- "GlaxoSmithKline seeks approval on first-ever malaria vaccine - Fortune".
- R. P. T. Davenport-Hines, Judy Slinn, Glaxo: A History to 1962, Cambridge University Press, 1992, pp. 7–13.
- David Newton, Trademarked: A History of Well-Known Brands, from Airtex to Wright's Coal Tar, The History Press, 2012, p. 435.
- "GSK History". GlaxoSmithKline. Retrieved 18 April 2011.
- Mark S. Lesney. The ghosts of pharma past. Modern Drug Discovery. January, 2004 pp. 25-26.
- David J. Ravenscraft, William F. Long. Paths to Creating Value in Pharmaceutical Mergers. Chapter in Mergers and Productivity, edited by Steven N. Kaplan. University of Chicago Press. January 2000. ISBN 0-226-42431-6
- "Glaxo warns of redundancies". The Independent. 21 June 1995.
- "10,000 face Glaxo's axe at Wellcome". The Independent. 15 June 1995. Retrieved 15 July 2012.
- "Glaxo Wellcome plans to axe 7,500 jobs". The Independent. 8 September 1995. Retrieved 15 July 2012.
- New York Times, January 27, 1995. Glaxo to Acquire Affymax
- "Outlook: Glaxo Wellcome". The Independent. 30 March 1999.
- "Profile: Glaxo Wellcome". BBC News. 17 January 2000.
- "Company of the week: Glaxo Wellcome". The Independent. 1 August 1999.
- "The new alchemy – The drug industry’s flurry of mergers is based on a big gamble". The Economist. 20 January 2000.
- "Partners resolve their differences and unite at the second attempt". Nature. 11 May 2000.
- "Annual Report 2013" (PDF). Retrieved 26 May 2014.
- "Most-recognized brands: Anti-infectives, December 2013 - Drugs.com MedNews".
- Geddes AM et al. Introduction: historical perspective and development of amoxicillin/clavulanate. Int J Antimicrob Agents. 2007 Dec;30 Suppl 2:S109-12. PMID 17900874
- Brown AG. Clavulanic acid, a novel beta-lactamase inhibitor--a case study in drug discovery and development. Drug Des Deliv. 1986 Aug;1(1):1-21. PMID 3334541
- Richards DM, Brogden RN; Brogden (February 1985). "Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use". Drugs 29 (2): 105–61. doi:10.2165/00003495-198529020-00002. PMID 3884319.
- "WHO Model List of Essential Medicines. 18th list" (PDF). October 2013.
- "Our consumer healthcare products"[dead link], GSK.
- "About us: what we do"[dead link], GlaxoSmithKline, accessed 16 November 2013
- "GlaxoSmithKline Completes the Purchase of Block Drug for $1.24 Billion". PR Newswire. Retrieved 1 August 2010.
- "Hall that glitters isn't shareholder gold". The Daily Telegraph (London). 15 July 2002.
- "Glaxo unit buys Breathe Right maker". Trib Live. 9 October 2006.
- Hirschler, Ben (24 May 2007). "Glaxo China R&D centre to target neurodegeneration". Reuters.
- "Pharmaceutical futures: Made in China?". Nature. 29 October 2008.
- Graham Ruddick (20 April 2009). "GlaxoSmithKline buys Stiefel for $3.6bn". The Daily Telegraph (London).
- Dana Cimilluca and Jeanne Whalen for the Wall Street Journal. 20 April 2009. Glaxo to Buy Stiefel for $2.9 Billion
- "FDA Approves Additional Vaccine for 2009 H1N1 Influenza Virus". US Food and Drug Administration (FDA). 16 November 2009.
- Andrew Jack (16 April 2009). "Companies / Pharmaceuticals – GSK and Pfizer to merge HIV portfolios". Financial Times.
- GSK Acquires Laboratorios Phoenix for $253m, InfoGrok.
- Paul Sandle (13 December 2010). "UPDATE 2-Glaxo buys protein-drinks firm Maxinutrition". Reuters.
- David Ranii (21 December 2011). "GSK sells BC, Goody's and other brands". News & Observer.
- "GSK confirms 500 mln stg UK investment plans", Reuters, 22 March 2012.
- European Biotechnology News 16 May 2012. GSK acquires Cellzome 100%: Britain's largest drugmaker GlaxoSmithKline will pay about €75m in cash to acquire Cellzome AG completely
- John Carroll for FierceBiotech 15 May 2012 GSK snags proteomics platform tech in $98M Cellzome buyout
- John Carroll for FiercePharma. 12 June 2012 GSK continues deal spree with $302M pact for Basilea eczema drug
- Basilea Pharmaceutica Press Release. 11 June 2012 Basilea enters into global agreement with Stiefel, a GSK company, for Toctino® (alitretinoin)
- GSK aims to market world's first malaria vaccine, Reuters, 2013
- Matthew Herper for Forbes. 16 July 2012. Three Lessons From GlaxoSmithKline's Purchase Of Human Genome Sciences
- Hirschler, Ben (10 March 2014). "GSK pays $1 billion to lift Indian unit stake to 75 percent". Reuters. Retrieved 10 March 2014.
- Aaron Smith for CNN Money, March 27, 2014 Alli weight-loss drug recalled for tampering
- Chad Bray and David Jolly for the New York Times. 22 April 2014. Novartis and Glaxo Agree to Trade $20 Billion in Assets
- Jonathan D. Rockoff, Jeanne Whalen, and Marta Falconi for the Wall Street Journal. 22 April 2014 Deal Flurry Shows Drug Makers' Swing Toward Specialization Accessed May 25, 2014
- "GEN - News Highlights:GSK Acquires GlycoVaxyn for $190M". GEN.
- "Access to medicine" (PDF).[dead link]
- Human Rights Campaign. Profle: Buyers Guide entry for GlaxoSmithKline. Accessed May 16, 2014
- "Global alliance to eliminate Lymphatic Filariasis". Ifpma.org. Archived from the original on 27 December 2008.
- "Private and Public Partners Unite to Combat 10 Neglected Tropical Diseases by 2020". Bill & Melinda Gates Foundation. 30 January 2012.
"Research-based pharma pledges on neglected tropical diseases". The Pharma Letter. 31 January 2012.
- "Press release: Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children - PATH".
- Birkett AJ et al. Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. Vaccine. 2013 Apr 18;31 Suppl 2:B233-43. PMID 23598488
- "Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children, Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children | 2013 | Press releases | Media | GlaxoSmithKline".[dead link]
- Donald G. McNeil Jr (18 October 2011). "Glaxo's RTS, S Malaria Vaccine Shows Promise, Scientists Say". The New York Times.
- Sarah Boseley, "Drug giant GlaxoSmithKline pledges cheap medicine for world's poor", The Guardian, 13 February 2009.
- UNITAID 16 February 2009. UNITAID Statement on GSK Patent Pool For Neglected Diseases
- Dr Tido von Schoen-Angerer, director of Médecins Sans Frontières' Campaign for Access to Essential Medicines. 16 February 2009. The Guardian: Letter in response to GSK's patent pool proposal
- "www.gsk.com" (PDF).
- U.S. Department of Justice Press Release. 2 July 2012 GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data
- Katie Thomas and Michael S. Schmidt (2 July 2012). "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times.
- S.E. Nissen (April 2010). "The rise and fall of rosiglitazone". Eur. Heart J. 31 (7): 773–6. doi:10.1093/eurheartj/ehq016. PMID 20154334.
- Thomas F. Lüscher, Ulf Landmesser, Frank Ruschitzka (May 2010). "Standing firm—the European Heart Journal, scientific controversies and the industry" (PDF). Eur. Heart J. 31 (10): 1157–8. doi:10.1093/eurheartj/ehq127. PMID 20418345.
- Max Baucus and Chuck Grassley (12 July 2010), "Finance Committee Letter to the FDA Regarding Avandia", Finance Committee
- ""The intimidation of Dr. John Buse and the diabetes drug Avandia"" (PDF). Committee on Finance, United States Senate. November 2007.
- Andrew Clark (22 November 2007). "GSK accused of trying to intimidate critic". The Guardian.
- "www.fda.gov" (PDF).
- Nissen SE, Wolski K; Wolski (July 2010). "Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality". Arch. Intern. Med. 170 (14): 1191–1201. doi:10.1001/archinternmed.2010.207. PMID 20656674.
- "F.D.A. Lifts Some Restrictions on Avandia - NYTimes.com".
- "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times. 2 July 2012.
- "Judge: Paxil ads can't say it isn't habit-forming". USA Today. 20 August 2002.
- Simon Garfield (29 April 2002). "The Chemistry of Happiness". The Guardian.
- W. Kondro and B. Sibbald (March 2004). "Drug company experts advised staff to withhold data about SSRI use in children". CMAJ 170 (5): 783. doi:10.1503/cmaj.1040213. PMC 343848. PMID 14993169.
- "WHO Expert Committee on Drug Dependence - Thirty-third Report", - WHO Technical Report Series, No. 915, 2003, pp. 20, 25.
- Marcia Angell (15 January 2009). "Drug Companies & Doctors: A Story of Corruption". New York Review of Books 56 (1).
- Alison Bass, Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial, Algonquin Books of Chapel Hill, 2008.
- U.S. Department of Justice Press Release. 26 October 2010 GlaxoSmithKline to Plead Guilty & Pay $750 Million to Resolve Criminal and Civil Liability Regarding Manufacturing Deficiencies at Puerto Rico Plant
- "Glaxo to Pay $750 Million for Sale of Bad Products". The New York Times. 27 October 2010.
- Tony Jaques, "When an Icon Stumbles – The Ribena Issue Mismanaged, Corporate Communications: An International Journal, 13(4), 2008, pp. 394–406.
- Linus Gregoriadis, "Makers of Ribena lose fight over anti-decay claims", The Daily Telegraph, 18 January 2001.
- David Eames (28 March 2007). "NZ Herald".
- BBC News, 12 March 2002 "Glaxo probed over doctor freebies"
- Jane Burgermeister for BMJ News. 5 June 2004 German prosecutors probe again into bribes by drug companies
- Reuters. September 12, 2006 GlaxoSmithKline to Settle Tax Dispute With U.S.
- US IRS Press Release. 11 September 2006 IRS Accepts Settlement Offer in Largest Transfer Pricing Dispute
- Alice Yan and Toh Han Shih (16 July 2013). "Shanghai travel agent's revenue surge led to arrests in GSK bribery case". South China Morning Post.
- "GlaxoSmithKline executives face China bribery probe". BBC News. 11 July 2013.
- "GSK response to China investigation". Gsk.com.[dead link]
- Rupert Neate and Angela Monaghan, GlaxoSmithKline admits some staff in China involved in bribery , The Guardian, 22 July 2013.
- Tom Philips (26 July 2013). "Chinese police allege Glaxo sales reps trained to offer sexual bribes". The Daily Telegraph (London).
- "China fines GlaxoSmithKline $490m over bribery". BBC. 19 September 2014. Retrieved 19 September 2014.
- Julia Kollewe (28 May 2014). "GlaxoSmithKline faces criminal investigation by Serious Fraud Office". The Guardian.
- "GlaxoSmithKline to be investigated by UK fraud body". BBC News. 27 May 2014.
- Official website
- GlaxoSmithKline companies grouped at OpenCorporates
- Financial Times Quote, profile, and news
- London Stock Exchange Quote, regulatory filings, and news[dead link]
- New York Stock Exchange Quote, profile, regulatory filings, and news